Industry
Biotechnology
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from dijoy@benzinga.com
March 28, 2024 | 9:01 pm
Portfolio Pulse from Avi Kapoor
March 11, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
February 20, 2024 | 4:59 pm
Portfolio Pulse from Benzinga Newsdesk
February 20, 2024 | 1:32 pm
Portfolio Pulse from Benzinga Newsdesk
February 16, 2024 | 5:45 pm
Portfolio Pulse from Avi Kapoor
February 08, 2024 | 6:07 pm
Portfolio Pulse from Avi Kapoor
February 08, 2024 | 5:36 pm
Portfolio Pulse from Benzinga Insights
February 08, 2024 | 5:31 pm
Portfolio Pulse from Henry Khederian
February 08, 2024 | 4:20 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.